

Supplementary Information: Tables S1-S3

External validation of prognostic and predictive gene signatures in head and neck cancer patients

Erlend I. F. Fossen^{*}, Mauricio Moreira-Soares, Marissa LeBlanc, Arnaldo Frigessi, Eivind Hovig, Laura López-Pérez, Estefanía Estévez-Priego, Liss Hernandez, Maria Fernanda Cabrera-Umpierrez, Giuseppe Fico, Ingeborg Tinhofer, Vanessa Sachse, Kathrin Scheckenbach, Christophe Le Tourneau, Maud Kamal, Steve Thomas, Miranda Pring, Lisa Licitra, Loris De Cecco, Stefano Cavalieri

*Corresponding author, erlend.fossen@cicero.oslo.no

Table S1. Datasets screened in this study showing number of screened patients (N) and number of eligible patients per dataset and clinical scenario. Study ID is the ID used in this manuscript. Study short name is original short study name. OS = overall survival. DFS = disease-free survival.

Study ID	Study short name	Provider	ClinicalTrials.gov ID	N	Eligible for 172-GS, 3 clusters HPV and RSI signatures		Eligible for pancancer-cisplatin and Cl3-hypoxia signatures	
					OS	DFS	OS	DFS
BD2_INT_MI	BD2Decide INT	Istituto Nazionale dei Tumori	NCT02832102	310	310	310	310	310
BD2_UDUS	BD2Decide UDUS	Charite - subcontractor	NCT02832102	127	127	127	127	127
GECO110	GECO110	Istituto Nazionale dei Tumori		107	107	107	0	0
Charite_ARO0401	ARO 04-01 Def-RCT	Charite	NCT02059668	58	0	0	0	0
Charite_DKTKROdef	DKTKRO Def-RCT	Charite	NCT02059668	63	0	0	0	0
PROGOR1	Curie PROGOR 1	Curie		120	0	0	0	0
PROGOR3	Curie PROGOR 3	Curie		99	0	0	0	0
SCANDARE	SCANDARE	Curie	NCT03017573	80	32	0	0	0
TCGA	TCGA-HNSC	Public		528	424	363	313	263
GSE41613	GSE41613	Public		97	97	0	0	0
Total	SuPerTreat			1589	1097	907	750	700

Table S2. Cohort characteristics for head and neck cancer patients used to test the radiosensitivity index (*RSI*). The disease-free survival (DFS) dataset is a subset of the overall survival dataset, where patients without data on DFS are excluded.

	Overall survival dataset (N=1097)	Disease-free survival dataset (N=907)
RSI score		
Mean (SD)	0.0 (1.0)	0.0 (1.0)
Median (Min, Max)	-0.1 (-2.5, 4.6)	-0.1 (-2.4, 3.5)
Radiotherapy treatment		
No	208 (19.0%)	146 (16.1%)
Yes	752 (68.6%)	633 (69.8%)
Missing	137 (12.5%)	128 (14.1%)
Study ID		
BD2_INT_MI	310 (28.3%)	310 (34.2%)
BD2_UDUS	127 (11.6%)	127 (14.0%)
GECO110	107 (9.8%)	107 (11.8%)
GSE41613	97 (8.8%)	0 (0%)
SCANDARE	32 (2.9%)	0 (0%)
TCGA	424 (38.7%)	363 (40.0%)
Clinical age at diagnosis		
Mean (SD)	61.0 (11.9)	60.8 (11.7)
Median (Min, Max)	61.0 (19.0, 93.0)	61.0 (19.0, 93.0)
Clinical sex		
Male	794 (72.4%)	660 (72.8%)
Female	303 (27.6%)	247 (27.2%)
cTN disease extension at diagnosis		
Early disease	161 (14.7%)	98 (10.8%)
Locoregionally advanced disease	936 (85.3%)	809 (89.2%)
Tumor region and HPV-status		
Oropharynx and HPV-positive	156 (14.2%)	151 (16.6%)
Hypopharynx	55 (5.0%)	52 (5.7%)
Larynx	165 (15.0%)	150 (16.5%)
Oral cavity	598 (54.5%)	451 (49.7%)
Oropharynx and HPV-negative	71 (6.5%)	67 (7.4%)
Missing	52 (4.7%)	36 (4.0%)
Smoking		
Never	230 (21.0%)	213 (23.5%)
Current_Former	653 (59.5%)	609 (67.1%)
Missing	214 (19.5%)	85 (9.4%)
Undergone cancer surgery		
No	187 (17.0%)	187 (20.6%)
Yes	854 (77.8%)	672 (74.1%)
Missing	56 (5.1%)	48 (5.3%)
Systemic treatment		
No	302 (27.5%)	233 (25.7%)
Yes	461 (42.0%)	426 (47.0%)
Missing	334 (30.4%)	248 (27.3%)

Table S3. Cohort characteristics for head and neck cancer patients used to test gene signatures *pancancer-cisplatin* and *Cl3-hypoxia*. The disease-free survival (DFS) dataset is a subset of the overall survival dataset, where patients without data on DFS are excluded.

	Overall survival dataset (N=750)	Disease-free survival dataset (N=700)
Pancancer-cisplatin score		
Mean (SD)	0.0 (1.0)	0.0 (1.0)
Median (Min, Max)	0.0 (-4.8, 4.8)	0.0 (-5.1, 4.8)
Cl3-hypoxia score		
Mean (SD)	0.0 (1.0)	0.0 (1.0)
Median (Min, Max)	0.0 (-3.2, 3.1)	0.0 (-3.4, 3.2)
Systemic agent (platinum)		
Platinum-based	362 (48.3%)	338 (48.3%)
Non-platinum-based	51 (6.8%)	47 (6.7%)
No systemic treatment	155 (20.7%)	154 (22.0%)
Missing systemic treatment	182 (24.3%)	161 (23.0%)
Systemic agent (cetuximab)		
Cetuximab-based	35 (4.7%)	32 (4.6%)
Non-cetuximab-based	378 (50.4%)	353 (50.4%)
No systemic treatment	155 (20.7%)	154 (22.0%)
Missing systemic treatment	182 (24.3%)	161 (23.0%)
Study ID		
BD2_INT_MI	310 (41.3%)	310 (44.3%)
BD2_UDUS	127 (16.9%)	127 (18.1%)
TCGA	313 (41.7%)	263 (37.6%)
Clinical age at diagnosis		
Mean (SD)	61.2 (11.0)	61.2 (11.1)
Median (Min, Max)	61.0 (20.0, 93.0)	61.0 (20.0, 93.0)
Clinical sex		
Male	560 (74.7%)	522 (74.6%)
Female	190 (25.3%)	178 (25.4%)
Tumor stage (TNM 7th edition)		
Stage III	177 (23.6%)	167 (23.9%)
Stage IV	573 (76.4%)	533 (76.1%)
Tumor region and HPV-status		
Oropharynx and HPV-positive	145 (19.3%)	144 (20.6%)
Hypopharynx	53 (7.1%)	51 (7.3%)
Larynx	149 (19.9%)	139 (19.9%)
Oral cavity	303 (40.4%)	274 (39.1%)
Oropharynx and HPV-negative	65 (8.7%)	65 (9.3%)
Missing	35 (4.7%)	27 (3.9%)
Smoking		
Never	188 (25.1%)	173 (24.7%)
Current or Former	550 (73.3%)	515 (73.6%)
Missing	12 (1.6%)	12 (1.7%)
Undergone cancer surgery		
No	187 (24.9%)	187 (26.7%)
Yes	519 (69.2%)	475 (67.9%)
Missing	44 (5.9%)	38 (5.4%)
Radiotherapy treatment		
No	84 (11.2%)	79 (11.3%)
Yes	585 (78.0%)	545 (77.9%)
Missing	81 (10.8%)	76 (10.9%)